Enhabit (EHAB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Feb, 2026Executive summary
Agreement reached for acquisition by Kinderhook Industries, marking a significant milestone and new chapter for the organization.
Leadership emphasizes continuity in mission, values, and day-to-day operations during the transition period.
Transition to private ownership expected to provide resources and support for strategic execution and growth.
Forward-looking statements highlight optimism about future opportunities and the partnership's potential.
Voting matters and shareholder proposals
A special meeting of stockholders will be called to obtain approval for the proposed acquisition transaction.
Proxy materials, including preliminary and definitive proxy statements, will be filed and made available to investors.
Board of directors and corporate governance
Directors and executive officers are identified as participants in the solicitation of proxies for the transaction.
Additional information on directors and officers is available in the company's prior definitive proxy statement.
Latest events from Enhabit
- Pending merger with Kinderhook Industries follows a year of revenue growth and operational improvement.EHAB
Proxy Filing5 Mar 2026 - Revenue and EBITDA rose, leverage fell, and a merger is pending.EHAB
Q4 20255 Mar 2026 - Kinderhook Industries to acquire Enhabit; shareholders to receive $13.80 per share upon closing.EHAB
Proxy Filing23 Feb 2026 - Pending acquisition will take the company private, subject to shareholder approval in 2026.EHAB
Proxy Filing23 Feb 2026 - Stockholders to receive $13.80 per share in a $1.1B buyout, pending approvals.EHAB
Proxy Filing23 Feb 2026 - Adjusted EBITDA rose 5.4% as non-Medicare admissions and hospice growth offset revenue softness.EHAB
Q2 20242 Feb 2026 - Growth driven by payer contract expansion, operational efficiency, and disciplined capital use.EHAB
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Diversified contracts and operational gains drive growth despite Medicare headwinds.EHAB
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Adjusted EBITDA up 5.6%, but goodwill impairment drove a $110.2M net loss; hospice grew 11%.EHAB
Q3 202416 Jan 2026